L. Hart

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

H. S. Hochster, Lauri Welles, L. Hart et al. · Journal of Clinical Oncology · 2005 · 58 citations

Medicine, Oncology, Pharmacology +12

Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)

Erminia Massarelli, V.A. Miller, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2007 · 40 citations

Medicine, Oncology, Pharmacology +16

A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).

Howard A. Burris, H. A. Burris, MN Saleh et al. · Cancer Research · 2009 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17

41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer

R. Natale, Mark A. Socinski, L. Hart et al. · European Journal of Cancer · 2014 · 17 citations

Pharmacy, Oncology, Pharmaceutics +17

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.

Alberto Bessudo, Johanna C. Bendell, N. Gabrail et al. · Journal of Clinical Oncology · 2011 · 17 citations

Medicine, Oncology, Pharmacology +14